Side-by-side · Research reference
TesamorelinvsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedVerified27/68 cited
BFDA-ApprovedVerified14/45 cited
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Tesamorelin
Tirzepatide
Primary target
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
Yes — physiological pulsatility preserved
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
02Dosage Protocols
Parameter
Tesamorelin
Tirzepatide
Frequency
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
—
Evidence basis
RCT / FDA-approvedFalutz 2007Falutz 2010
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
12–52 weeks
VAT returns within months of stopping.
Indefinite for chronic indication
Reconstitution
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
Empty stomach, pre-sleep preferred
Once weekly, any time of day
Half-life
~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010
Modified vs native GHRH (7 min t½).
~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
03Metabolic / Fat Loss Evidence
Parameter
Tesamorelin
Tirzepatide
Primary fat target
Visceral adipose tissue (VAT) — abdominal
—
Effect on lean mass
Modest lean mass preservation / slight increase
—
Effect reversibility
VAT returns within months of stopping
—
Key publication
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
—
04Side Effects & Safety
Parameter
Tesamorelin
Tirzepatide
Injection site reaction
Erythema, pruritus, redness (common)
Mild erythema, pruritus
Fluid retention / Edema
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
—
IGF-1 elevation
Dose-dependent; supraphysiological levels = discontinue
—
Cancer risk
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
—
Antibody formation
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
—
GI symptoms
Nausea, diarrhea (mild, transient)
Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
Tesamorelin
Tirzepatide
1. Reconstitution
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Needle
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
Pen-supplied. Research vial: 27–31G insulin syringe.
06Stack Synergy
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality
Tirzepatide
— no documented stacks